Scientists have known for more than 30 years that intracellular proteins are central to the pathogenesis of many diseases.
Many intracellular proteins have been and continue to be considered “undruggable”.
Antibodies are able to bind their targets but are widely believed to be unable to penetrate the cell membrane.
Biologic therapies, such as single domain antibodies, are substances derived from living organisms used to treat specific diseases.
There is great interest in these types of therapy because they are enabling the personalized treatment of many diseases, including cancer, infections, inflammatory, and central nervous system diseases.
With more than 25 therapeutic antibody compounds on the market and with more than 100 undergoing clinical trials, it has become increasingly evident that engineered antibodies have come of age as viable biopharmaceuticals.